scholarly journals Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study

2012 ◽  
Vol 206 (2) ◽  
pp. 141.e1-141.e8 ◽  
Author(s):  
Irene T. Lindenburg ◽  
Vivianne E. Smits-Wintjens ◽  
Jeanine M. van Klink ◽  
Esther Verduin ◽  
Inge L. van Kamp ◽  
...  
Keyword(s):  
Neurodevelopmental Outcome ◽  
Hemolytic Disease ◽  
Intrauterine Transfusion

Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease

1998 ◽  
Vol 179 (4) ◽  
pp. 858-863 ◽  
Author(s):  
Lynda Hudon ◽  
Kenneth J. Moise ◽  
Suzanne E. Hegemier ◽  
Reba M. Hill ◽  
Alicia A. Moise ◽  
...  
Keyword(s):  
Neurodevelopmental Outcome ◽  
Hemolytic Disease ◽  
Intrauterine Transfusion

scholarly journals Immunoglobulins in Neonates with Rhesus Hemolytic Disease of the Fetus and Newborn: Long-Term Outcome in a Randomized Trial

2015 ◽  
Vol 39 (3) ◽  
pp. 209-213 ◽  
Author(s):  
Jeanine M.M. van Klink ◽  
Suzanne J. van Veen ◽  
Vivianne E.H.J. Smits-Wintjens ◽  
Irene T.M. Lindenburg ◽  
Monique Rijken ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Placebo Group ◽  
Controlled Trial ◽  
Neurodevelopmental Outcome ◽  
Hemolytic Disease ◽  
Follow Up Study ◽  
Randomized Controlled ◽  
Neurodevelopmental Impairment

Objective: Prophylactic intravenous immunoglobulin (IVIg) does neither reduce the need for exchange transfusion nor the rates of other adverse neonatal outcomes in neonates with rhesus hemolytic disease of the fetus and newborn (rhesus HDFN) according to our randomized controlled trial analysis. Our objective was to assess the long-term neurodevelopmental outcome in the children included in the trial and treated with either IVIg or placebo. Methods: All families of the children included in the trial were asked to participate in this follow-up study. The long-term neurodevelopmental outcome in children at least 2 years of age was assessed using standardized tests. The primary outcome was the incidence of neurodevelopmental impairment defined as at least one of the following: cerebral palsy, severe cognitive and/or motor developmental delay (with a test score of less than -2 SD), bilateral deafness or blindness. Results: Sixty-six of the 80 children (82.5%) who had been recruited to the initial randomized controlled trial participated in the follow-up study. The children were assessed at a median age of 4 years (range 2-7). The median cognitive score was 96 (range 68-118) in the IVIg group and 97 (range 66-118) in the placebo group (p = 0.79). There was no difference in the rate of neurodevelopmental impairment between the IVIg and the placebo group [3% (1/34) vs. 3% (1/32); p = 1.00]. Conclusions: The long-term neurodevelopmental outcome in children treated with IVIg was not different from that in children treated with placebo. Standardized long-term follow-up studies with large enough case series and sufficient power are needed to replicate these findings.

Long-term neurodevelopmental outcome after intrauterine transfusion for fetal anemia

2011 ◽  
Vol 87 (9) ◽  
pp. 589-593 ◽  
Author(s):  
Jeanine M.M. van Klink ◽  
Hendrik M. Koopman ◽  
Dick Oepkes ◽  
Frans J. Walther ◽  
Enrico Lopriore
Keyword(s):  
Neurodevelopmental Outcome ◽  
Fetal Anemia ◽  
Intrauterine Transfusion

Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome

2012 ◽  
Vol 206 (3) ◽  
pp. 204.e1-204.e5 ◽  
Author(s):  
Eveline P. De Jong ◽  
Irene T. Lindenburg ◽  
Jeanine M. van Klink ◽  
Dick Oepkes ◽  
Inge L. van Kamp ◽  
...  
Keyword(s):  
Parvovirus B19 ◽  
Neurodevelopmental Outcome ◽  
Intrauterine Transfusion ◽  
Parvovirus B19 Infection

scholarly journals Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Francesca Garofoli ◽  
Stefania Longo ◽  
Camilla Pisoni ◽  
Patrizia Accorsi ◽  
Micol Angelini ◽  
...  
Keyword(s):  
Preterm Birth ◽  
Preterm Infants ◽  
Neurodevelopmental Outcome ◽  
Lipid Peroxidation Product ◽  
Cerebral Magnetic Resonance Imaging ◽  
Neurodevelopmental Impairment ◽  
Anti Oxidant ◽  
Preterm Newborns

Abstract Background Prevention of neurodevelopmental impairment due to preterm birth is a major health challenge. Despite advanced obstetric and neonatal care, to date there are few neuroprotective molecules available. Melatonin has been shown to have anti-oxidant/anti-inflammatory effects and to reduce brain damage, mainly after hypoxic ischemic encephalopathy. The planned study will be the first aiming to evaluate the capacity of melatonin to mitigate brain impairment due to premature birth. Method In our planned prospective, multicenter, double-blind, randomized vs placebo study, we will recruit, within 96 h of birth, 60 preterm newborns with a gestational age ≤ 29 weeks + 6 days; these infants will be randomly allocated to oral melatonin, 3 mg/kg/day, or placebo for 15 days. After the administration period, we will measure plasma levels of malondialdehyde, a lipid peroxidation product considered an early biological marker of melatonin treatment efficacy (primary outcome). At term-equivalent age, we will evaluate neurological status (through cerebral ultrasound, cerebral magnetic resonance imaging, vision and hearing evaluations, clinical neurological assessment, and screening for retinopathy of prematurity) as well as the incidence of bronchodysplasia and sepsis. We will also monitor neurodevelopmental outcome during the first 24 months of corrected age (using the modified Fagan Test of Infant Intelligence at 4–6 months and standardized neurological and developmental assessments at 24 months). Discussion Preterm birth survivors often present long-term neurodevelopmental sequelae, such as motor, learning, social-behavioral, and communication problems. We aim to assess the role of melatonin as a neuroprotectant during the first weeks of extrauterine life, when preterm infants are unable to produce it spontaneously. This approach is based on the supposition that its anti-oxidant mechanism could be useful in preventing neurodevelopmental impairment. Considering the short- and long-term morbidities related to preterm birth, and the financial and social costs of the care of preterm infants, both at birth and over time, we suggest that melatonin administration could lead to considerable saving of resources. This would be the first study addressing the role of melatonin in very low birth weight preterm newborns, and it could provide a basis for further studies on melatonin as a neuroprotection strategy in this vulnerable population. Trial registration ClinicalTrials.gov NCT04235673. Prospectively registered on 22 January 2020.

scholarly journals Long-Term Neurodevelopmental Outcome of Monochorionic and Matched Dichorionic Twins

PLoS ONE ◽  
2009 ◽  
Vol 4 (8) ◽  
pp. e6815 ◽  
Author(s):  
Karien E. A. Hack ◽  
Corine Koopman-Esseboom ◽  
Jan B. Derks ◽  
Sjoerd G. Elias ◽  
Martin J. K. de Kleine ◽  
...  
Keyword(s):  
Neurodevelopmental Outcome

390: Long-term neurodevelopmental outcome in twin-to-twin transfusion syndrome (TTTS) in the eurofoetus trial

2008 ◽  
Vol 199 (6) ◽  
pp. S118 ◽  
Author(s):  
Lisa Örtqvist ◽  
Bussieres Laurence ◽  
Staraci Stephanie ◽  
Fermanian Christophe ◽  
Ville Yves
Keyword(s):  
Neurodevelopmental Outcome

scholarly journals Neurodevelopmental outcome of babies with hypoxic ischemic encephalopathy

2017 ◽  
Vol 5 (7) ◽  
pp. 3197
Author(s):  
Sirajuddin Nazeer ◽  
Senthilkumar K. ◽  
Thangavel A. ◽  
Uma Maheswari M.
Keyword(s):  
Neurological Outcome ◽  
Neurodevelopmental Outcome ◽  
Hypoxic Ischemic Encephalopathy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Mri Brain ◽  
Early Markers ◽  
Cdc Grading ◽  
Ischemic Encephalopathy

Background: The aim of the study was to find out the neurodevelopmental outcome of babies with hypoxic ischemic encephalopathy at 6 months of age and to predict early markers of abnormal neurological outcome in those babies.Methods: 50 babies admitted with hypoxic ischemic encephalopathy were enrolled in this prospective study and followed up at 3 and 6 months of age at Mahatma Gandhi Memorial Government Hospital, Trichy. The neurological outcome of the babies was assessed by CDC grading of motor milestones, Trivandrum development screening chart, Amiel Tison angles head circumference and weight measured. USG cranium was done for all the babies and MRI brain was done in babies with abnormal neuro sonogram and abnormal outcome. Vision and hearing were tested clinically.Results: The incidence of abnormal neurological outcome was 14%. The early markers predicting abnormal neurological sequele are identified.Conclusions: Early identification of abnormal neuro behaviour helps in starting early intervention to improve the long term outcome.

Sign in / Sign up

Export Citation Format

Share Document